Mapping large numbers of results may take a few moments.
|Company AskBio||Activity: Research and Development||Company Description Asklepios BioPharmaceutical (AskBio) uses adeno-associated virus (AAV) technology to develop and manufacture gene therapies for rare diseases and other genetic disorders.||Location Research Triangle Park|
|Company BioCryst Pharmaceuticals Inc.||Activity: Research and Development||Company Description BioCryst Pharmaceuticals designs and develops novel, small-molecule oral drugs that block key enzymes to treat rare diseases. The Durham location houses BioCryst's clinical, regulatory and executive teams.||Location Durham|
|Company Humacyte Inc.||Activity: Research and Development||Company Description Humacyte develops a technology platform that isolates and grows stable investigational human tissue replacements with potential regenerative medicine, vascular and nonvascular surgery applications.||Location Durham|
|Company Precision BioSciences Inc. (Durham)||Activity: Research and Development||Company Description Precision BioSciences is a clinical stage gene editing company using its novel ARCUS genome editing platform to develop new treatment options for cancer and genetic diseases.||Location Durham|
|Company StrideBio Inc.||Activity: Research and Development||Company Description StrideBio develops engineered viral vectors for gene therapy for the treatment of rare diseases. StrideBio's technology engine utilizes structure-inspired design to engineer AAV vectors which can escape pre-existing neutralizing antibodies (NAbs).||Location Research Triangle Park|